Dr Charles W Clogston, MD | |
10100 Kanis Rd, Little Rock, AR 72205-6202 | |
(501) 255-6000 | |
(501) 255-6400 |
Full Name | Dr Charles W Clogston |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 35 Years |
Location | 10100 Kanis Rd, Little Rock, Arkansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962449728 | NPI | - | NPPES |
127369001 | Medicaid | AR |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | E0428 (Arkansas) | Primary |
207UN0901X | Nuclear Medicine - Nuclear Cardiology | E0428 (Arkansas) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Chi-st Vincent Infirmary | Little rock, AR | Hospital |
Baptist Health Medical Center-stuttgart | Stuttgart, AR | Hospital |
Ashley County Medical Center | Crossett, AR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
St Vincent Infirmary Medical Center | 5698674166 | 49 |
News Archive
A study at the University Clinics of Bonn and Cologne gives people with therapy-resistant depression reason for hope.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.
Using a neuromuscular ultrasound technique, researchers reveal that COVID-19 patients have a very high prevalence of diaphragm dysfunction.
› Verified 3 days ago
Entity Name | Baptist Health |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578593067 PECOS PAC ID: 0648177949 Enrollment ID: O20031215000977 |
News Archive
A study at the University Clinics of Bonn and Cologne gives people with therapy-resistant depression reason for hope.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.
Using a neuromuscular ultrasound technique, researchers reveal that COVID-19 patients have a very high prevalence of diaphragm dysfunction.
› Verified 3 days ago
Entity Name | St Vincent Infirmary Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1316991847 PECOS PAC ID: 5698674166 Enrollment ID: O20040103000052 |
News Archive
A study at the University Clinics of Bonn and Cologne gives people with therapy-resistant depression reason for hope.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.
Using a neuromuscular ultrasound technique, researchers reveal that COVID-19 patients have a very high prevalence of diaphragm dysfunction.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Charles W Clogston, MD 10100 Kanis Rd, Little Rock, AR 72205-6202 Ph: (501) 255-6000 | Dr Charles W Clogston, MD 10100 Kanis Rd, Little Rock, AR 72205-6202 Ph: (501) 255-6000 |
News Archive
A study at the University Clinics of Bonn and Cologne gives people with therapy-resistant depression reason for hope.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.
Using a neuromuscular ultrasound technique, researchers reveal that COVID-19 patients have a very high prevalence of diaphragm dysfunction.
› Verified 3 days ago
Lonnie E Harrison, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7 Shackleford West Blvd, Little Rock, AR 72211 Phone: 501-664-5860 Fax: 501-664-0889 | |
Muthu Veera Kumaran, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 556, Little Rock, AR 72205 Phone: 501-686-6033 Fax: 501-686-8932 | |
Armaghan Yunis Soomro, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1701 S Shackleford Rd, Little Rock, AR 72211 Phone: 501-219-7282 Fax: 201-277-9765 | |
Tanvi Harishbhai Patel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 508, Little Rock, AR 72205 Phone: 501-686-7105 Fax: 501-526-5906 | |
Gaurav Dhar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Anthony R Giglia Iii, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5800 W 10th St, Ste 610 Freeway Medical Center, Little Rock, AR 72204 Phone: 501-661-9393 Fax: 501-663-4795 | |
Brian Bean, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: #2 St Vincent Circle, Little Rock, AR 72205 Phone: 501-552-3592 Fax: 501-552-4129 |